Patents by Inventor Daniel Wrapp

Daniel Wrapp has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • CROSS-REACTIVE CORONAVIRUS ANTIBODIES AND USES THEREOF
    Publication number: 20230348571
    Abstract: The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.
    Type: Application
    Filed: April 6, 2021
    Publication date: November 2, 2023
    Inventors: Ivelin Stefanov Georgiev, Andrea R. Shiakolas, Kevin J. Kramer, James E. Crowe, Jr., Robert Carnahan, Nianshuang Wang, Daniel Wrapp, Jason McLellan
  • ENGINEERED CORONAVIRUS SPIKE (S) PROTEIN AND METHODS OF USE THEREOF
    Publication number: 20230242594
    Abstract: Provided herein are engineered Coronavirus S proteins, such as engineered SARS-CoV-2 S proteins. In some aspects, the engineered S proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of engineered proteins as diagnostics, in screening platforms and/or in vaccine compositions.
    Type: Application
    Filed: May 28, 2021
    Publication date: August 3, 2023
    Applicants: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM, THE TRUSTEES OF DARTMOUTH COLLEGE
    Inventors: Jason MCLELLAN, Jennifer MAYNARD, Andrea CHASSE, Ilya FINKELSTEIN, Mohammad JAVANMARDI, Jeffrey SCHAUB, Hung-Che KUO, Chia-Wei CHOU, Jory GOLDSMITH, Christy HJORTH, Ching-Lin HSIEH, Patrick BYRNE, Nicole JOHNSON, Nianshuang WANG, Daniel WRAPP
  • CORONA VIRUS BINDERS
    Publication number: 20230227537
    Abstract: The present invention relates to the field of virology, more specifically to the field of zoonotic Coronaviruses. Specifically, the invention provides for binding agents specific for the spike protein receptor binding domain (RBD) of the SARS-Corona virus, more specifically for an epitope of the RBD present in a broad range of Sarbecoviruses and mutants thereof, even more specifically present in SARS-Cov and SARS-CoV-2 viruses. More specifically, the invention relates to compositions comprising antibodies capable of specifically binding and neutralizing SARS-Corona viruses.
    Type: Application
    Filed: February 5, 2021
    Publication date: July 20, 2023
    Inventors: Bert SCHEPENS, Xavier SAELENS, Nico CALLEWAERT, Dorien DE VLIEGER, Loes VAN SCHIE, Wim NERINCKX, Kenny ROOSE, Wander VAN BREEDAM, Hannah EECKHAUT, Daria FIJALKOWSKA, Chiara LONIGRO, Sieglinde DE CAE, Bruno DOMBRECHT, Catelijne STORTELERS, Johan NEYTS, Leen DELANG, Suzanne KAPTEIN, Joana DUARTE DA ROCHA PEREIRA, Barney GRAHAM, Jason MCLELLAN, Daniel WRAPP, Han REMAUT
  • SARS-COV-2 VACCINE
    Publication number: 20230113170
    Abstract: SARS-CoV-2 S ectodomain trimers stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the SARS-CoV-2 S ectodomain trimers and/or nucleic acid molecules can be used to generate an immune response to SARS-CoV-2 S in a subject, for example, an immune response that inhibits SARS-CoV-2 infection in the subject.
    Type: Application
    Filed: February 11, 2021
    Publication date: April 13, 2023
    Applicants: The United States of America, as represented by the Secretary, Department of Health and Human, Board of Regents, The University of Texas System, Trustees of Dartmouth College
    Inventors: Barney Graham, Kizzmekia Corbett, Olubukola Abiona, Geoffrey Hutchinson, Jason McLellan, Daniel Wrapp, Nianshuang Wang